However, in contrast to previous “all comer”trials, these studies will recruit a genetically more homogenous group ofexclusively iCCA patients, and will help to determine the prognostic and predictivevalue of FGFR2 fusions in biliary tract cancer. The gene discussed is FGFR2; the disease is biliary tract cancer.